Updated time: 2022-11-15 09:59:44
12A-1050930
TW I722252、JP 特許字第7015306號、CN ZL2017 8 006830.8
Clinical virotherapy has been successfully approved for use in cancer treatment by the US Food and Drug Administration (FDA), however a number of improvements are still sought to more broadly develop virotherapy. A particular challenge is to administer viral therapy systemically and overcome limitations in intra-tumoral injection, especially for complex tumor within sensitive organs. Here we show that recombinant adeno-associated virus serotype 2 (AAV2) chemically conjugated with iron oxide nanoparticles (~5 nm) have remarkable ability to be remotely guided under magnetic field. This technology demonstrates guided and highly localized micro-scale, light-triggered virotherapy.
- Decreasing of viral dosage
- Reducing of side-effect due to off-target
- Improvement of in vivo viral delivery
- Tumor therapy
- Gene silencing/repairing
- Light-triggered therapy
Pan-Chyr Yang、S.-Ja Tseng、Zi-Xian Liao
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Remote control of light-triggered virotherapy